Mochida Pharmaceutical Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Mochida Pharmaceutical Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Mochida Pharmaceutical Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Mochida Pharmaceutical Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Mochida Pharmaceutical Co Ltd (Mochida Pharma) primarily carries out the development of new drugs for the treatments of intractable diseases and generic drugs. The company helps treat conditions related to cardiology, obstetrics and gynecology, psychiatry, and gastroenterology. Mochida Pharma also offers treatments for conditions such as ulcerative colitis, chronic constipation and hyperlipidemia, arteriosclerosis obliterans, gout and hyperuricemia, pulmonary arterial hypertension, endometriosis, adenomyosis, and dysmenorrhea, among others. In the field of regenerative medicine, Mochida Pharma is developing treatments using human dental pulp stem cells, a purified mesenchymal stem cells, and the umbilical cord-derived cell drug HLC-001. Mochida Pharma distributes its products through specialty pharmacies and drugstores via mail orders. Mochida Pharma is headquartered in Shinjuku-Ku, Tokyo, Japan.
Headquarters
Japan
Address
1-7 Yotsuya, Shinjuku-Ku, Tokyo, 160-8515
Website
www.mochida.co.jp
Telephone
81 3 33587211
No of Employees
1,508
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4534 (TYO)
Revenue (2024)
$689.8M
2.2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
25%
(2024 vs 2023)
Market Cap*
$789.1M
Net Profit Margin (2024)
XYZ
22.4%
(2024 vs 2023)
* As of and is in US$
Mochida Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | - |
| Pharmaceutical Products | Lexapro |
| Sensitive Skin Care Products | Lialda |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In March, the company entered into an agreement to acquire URECE Tablets from Fuji Yakuhin. |
| 2026 | Regulatory Approval | In March, the company secured marketing approval for Tocilizumab BS MA in Japan. |
| 2026 | New Products/Services | In March, the company and Meiji Seika Pharma unveiled EPADEL S900 in Vietnam. |
Competitor Comparison
| Key Parameters | Mochida Pharmaceutical Co Ltd | Astellas Pharma Inc | Daiichi Sankyo Co Ltd | Kyowa Kirin Co Ltd | Nippon Shinyaku Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Shinjuku-Ku | Chuo-Ku | Chuo-Ku | Chiyoda-Ku | Kyoto |
| State/Province | Tokyo | Tokyo | Tokyo | Tokyo | Kyoto |
| No. of Employees | 1,508 | 13,643 | 19,765 | 5,161 | 2,243 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Naoyuki Mochida | Director; President; Chief Executive Officer | Executive Board | 1999 | - |
| Yutaka Kawakami, Ph.D. | Executive Vice President - Quality Assurance and Mochida Pharmaceutical Factory; Director | Executive Board | - | - |
| Junichi Sakaki, Ph.D. | Director; Executive Managing Officer-Business Development, Business Promotion and Biomaterials Business | Executive Board | - | - |
| Sakata Naka | Executive Vice President; Director | Executive Board | - | - |
| Keiichi Sagisaka | Executive Managing Director- Pharmaceutical Sales and Mochida Healthcare | Executive Board | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer